Accedi
logo

The NGF System and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain

Pfizer, Eli Lilly, Janssen and Regeneron are advancing a promising class of analgesic drugs, hoping to
put concerns around autonomic dysfunction and joint destruction behind them.

Read the article published on Nature Reviews Drug Discovery 14, 297–298 

Anti-NGF_Pain_Programmes_NatureRevDrugDiscov_2015-1 (1) ( PDF)

See also the post: FDA lifts clinical hold on Pfizer/Lilly’s tanezumab

Leave a reply

You must be logged in to post a comment.